Tower Research Capital (TRC)’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.27K Sell
1,302
-1,614
-55% -$11.2K ﹤0.01% 4416
2026
Q2
$21.5K Buy
2,916
+1,246
+75% +$12K ﹤0.01% 3483
2026
Q1
$21.1K Sell
1,670
-267
-14% -$3.06K ﹤0.01% 3448
2025
Q4
$19.9K Sell
1,937
-5,421
-74% -$45.7K ﹤0.01% 3103
2025
Q3
$42.7K Buy
7,358
+3,463
+89% +$20.3K ﹤0.01% 2655
2025
Q2
$26.2K Buy
3,895
+2,703
+227% +$21.7K ﹤0.01% 3517
2025
Q1
$10.8K Sell
1,192
-354
-23% -$4.41K ﹤0.01% 3608
2024
Q4
$26.7K Sell
1,546
-4,818
-76% -$87.3K ﹤0.01% 2971
2024
Q3
$102K Buy
6,364
+3,484
+121% +$54.9K ﹤0.01% 2224
2024
Q2
$41K Buy
2,880
+2,445
+562% +$34.8K ﹤0.01% 3244
2024
Q1
$6.16K Sell
435
-5,345
-92% -$75.6K ﹤0.01% 4421
2023
Q4
$87.2K Buy
5,780
+4,777
+476% +$70.8K ﹤0.01% 2747
2023
Q3
$15.8K Buy
1,003
+409
+69% +$6.44K ﹤0.01% 3590
2023
Q2
$8.99K Sell
594
-698
-54% -$9.6K ﹤0.01% 4350
2023
Q1
$19K Buy
1,292
+845
+189% +$11.3K ﹤0.01% 3514
2022
Q4
$6K Sell
447
-2,061
-82% -$36.1K ﹤0.01% 4774
2022
Q3
$40K Buy
+2,508
New +$31.8K ﹤0.01% 3360
2022
Q2
– Sell
-2,485
Closed -$23K – 6523
2022
Q1
$23K Buy
2,485
+7
+0.3% +$75 ﹤0.01% 3406
2021
Q4
$42K Buy
+2,478
New +$60.1K ﹤0.01% 2909

Other funds holding TRDA

Tower Research Capital (TRC)'s TRDA Position: Q3 2026 in Review

Tower Research Capital (TRC) reduced its Entrada Therapeutics (TRDA) stake by 55% in Q3 2026, selling an estimated $11.2K and leaving 1,302 shares worth $8.27K. The position accounts for ﹤0.01% of the portfolio, ranked #4416.

Tower Research Capital (TRC) first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $102K in Q3 2024. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Tower Research Capital (TRC) held 1,302 shares of Entrada Therapeutics worth $8.27K as of Q3 2026.
  • Tower Research Capital (TRC) sold 1,614 Entrada Therapeutics shares in Q3 2026, an estimated $11.2K.
  • Entrada Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4416 holding.
  • Tower Research Capital (TRC) first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Entrada Therapeutics position peaked at $102K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.